Sagimet climbs as acne therapy hits main goals in late-stage trial in China

Stock Information for Sagimet Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sagimet Biosciences Inc.

Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD-The Liver Meeting® 2025
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
Sagimet Biosciences Announces Upcoming Presentation at AASLD-The Liver Meeting® 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.